Vaccine Candidate Effective in Preventing Against RSV, Phase 2a Study Finds - AJMC.com Managed Markets Network

Results from a phase 2a study show that a bivalent prefusion F vaccine was effective against symptomatic respiratory syncytial virus (RSV) infection and viral shedding, with no identified safety concerns.

A single dose of a bivalent prefusion F (RSVpreF) vaccine candidate was shown to be effective in preventing symptomatic respiratory syncytial virus (RSV) infection and limited the duration of viral s… [+4112 chars]

full article...